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Abstract
Background: The prognostic value of histologic grade (HG) in invasive lobular
carcinoma (ILC) remains uncertain, and most ILC tumors are graded as HG2.
Genomic grade (GG) is a 97-gene signature that improves the prognostic value of
HG. This study evaluates whether GG may overcome the limitations of HG in ILC.
Methods: Gene expression data were generated from frozen tumor samples, and
GG calculated according to the expression of 97 genes. The prognostic value of
GG was assessed in a stratified Cox regression model for invasive disease-free
survival (IDFS) and overall survival (OS). Results: A total of 166 patients were
classified by GG. HG classified 33 (20%) tumors as HG1, 120 (73%) as HG2 and
12 (7%) as HG3. GG classified 106 (64%) tumors as GG low (GG1), 29 (17%)
as GG high (GG3) and 31 (19%) as equivocal (cases not classified as GG1 or
GG3). The median follow-up time was 6.5 years. In multivariate analyses, GG
was associated with IDFS [HRGG3 vs GG1 5.6 (2.1-15.3); P < 0.001] and O...
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Background: The prognostic value of histologic grade (HG) in invasive lobular carcinoma (ILC) remains uncertain, and
most ILC tumors are graded as HG2. Genomic grade (GG) is a 97-gene signature that improves the prognostic value of
HG. This study evaluates whether GG may overcome the limitations of HG in ILC.
Methods: Gene expression data were generated from frozen tumor samples, and GG calculated according to the
expression of 97 genes. The prognostic value of GG was assessed in a stratiﬁed Cox regression model for invasive
disease-free survival (IDFS) and overall survival (OS).
Results: A total of 166 patients were classiﬁed by GG. HG classiﬁed 33 (20%) tumors as HG1, 120 (73%) as HG2
and 12 (7%) as HG3. GG classiﬁed 106 (64%) tumors as GG low (GG1), 29 (17%) as GG high (GG3) and 31 (19%) as
equivocal (cases not classiﬁed as GG1 or GG3). The median follow-up time was 6.5 years. In multivariate analyses, GG was
associated with IDFS [HRGG3 vs GG1 5.6 (2.1–15.3); P< 0.001] and OS [HRGG3 vs GG1 7.2, 95% CI (1.6–32.2); P= 0.01].
Conclusions: GG outperformed HG in ILC and added prognostic value to classic clinicopathologic variables, including
nodal status.
Key words: breast cancer, genomics, lobular carcinoma, prognosis
introduction
Invasive lobular carcinoma (ILC) is the second most common
breast cancer subtype, accounting for 10% to 15% of breast
cancers. ILC differs from invasive ductal carcinoma (IDC)
with respect to epidemiology, clinical presentation and
responsiveness to systemic treatments [1–3].
The median incidence of ILC is disproportionately high
when compared with IDCs, particularly in Western countries
and among women older than 50 [4]. Moreover, ILCs are
less responsive to chemotherapy, more frequently bilateral at
the initial diagnosis and more prone to present bone,
gastrointestinal, peritoneal and ovarian metastases than
IDCs [2].
ILCs are often hormone receptor-positive tumors,
HER2-negative and present low-to-intermediate histologic
grade (HG 1 or 2). Nevertheless, a variant form of ILC
named pleomorphic invasive lobular carcinoma (PILC) is
characterized by a higher grade (HG3) than classical ILC and
often classiﬁed as HER2-positive [5].
In contrast to IDC, the prognostic value of HG in ILC is
not well established. Standard HG assessment by the
Elston–Ellis method is based on the semi-quantitative
evaluation of three morphologic features (tubule formation,
nuclear pleomorphism and mitotic count) [6]. However,
ILC tumors lack tubule formation, which hinders the
process of grading in this histologic subtype and results
in the classiﬁcation of approximately two-thirds of ILC
as HG2, which is non-informative for treatment
decision making.
Over the last decade, a number of genomic signatures have
shed light onto breast cancer classiﬁcation, allowing breast
cancer care to become more personalized [7]. With respect to
the management of estrogen receptor (ER)-positive breast
cancer, gene expression signatures have demonstrated their
ability to provide prognostic and predictive information
beyond what is possible with current classical clinicopathologic
parameters alone [7], though their value for use in clinical
†Presented in part at the American Society of Clinical Oncology (ASCO), 3–7 June
2011, Chicago, IL, USA (Poster discussion, Abstract No. 535).
*Correspondence to: Prof. C. Sotiriou, Breast Cancer Translation Research Laboratory
J.C. Heuson, Institut Jules Bordet, 121 Boulevard de Waterloo, 1000 Brussels,
Belgium. Tel: +32-2-541-34-57; Fax: +32-2-541-33-39; E-mail: christos.sotiriou@
bordet.be
Annals of Oncology original articles
© The Author 2012. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com
 at U
niversite catholique de Louvain on February 9, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
practice is still under investigation in prospective clinical
trials [8, 9].
Nevertheless, most studies using genomic signatures have
not considered different histologic subtypes separately. The
genomic grade (GG) is a 97-gene signature that improves the
prognostic value of HG in IDC [10]. With a view towards
improving treatment decision making for patients with ILC
in the future, we evaluated the prognostic performance of GG
in tumors from 166 patients diagnosed with primary ILC in
this present study.
patients and methods
patient selection
A retrospective series of frozen tumor samples from patients treated in
three different centers in Belgium and France [Institut Jules Bordet (IJB),
Brussels; Institut Paoli Calmettes, Marseille; and Cliniques Universitaires
Saint Luc, Brussels] was selected from the centers’ tissue banks according
to the following criteria: the tumor was primary ILC (classical ILC or PILC
histotype) diagnosed between January 1990 and December 2005; axillary
lymph node-negative or node-positive; no age limit; minimum 5 years’ of
clinical follow-up information was available; and there were no previous
malignancies, except non-melanoma skin cancer. All patients were treated
by breast surgery, followed by chemotherapy, endocrine therapy or
radiotherapy as indicated and per local guidelines. The study protocol was
approved by the ethics committee at each participating center.
tumor samples
Tumor samples classiﬁed either as classical ILC or PILC, with no other
invasive histologic type, were included in this analysis. E-cadherin staining
was performed at the time of diagnosis in cases of doubt about ILC versus
IDC diagnosis. Tumor size, HG (Elston–Ellis method), lymph node status,
Ki67 labeling index, ER and progesterone receptor (PR) were based on the
assessment provided by the local breast cancer pathologists at the time of
diagnosis. Ki67 was evaluated either as a continuous or categorical variable.
A Ki67 cut point of 14% (low <14% and high ≥14%) was applied to this
population, because this is the one considered best for separating luminal A
from luminal B breast cancer molecular subtypes as deﬁned by Perou et al.
[11, 12]. Owing to variations in hormone receptors and HER2 assessment
over time, we also evaluated ER and HER2 status using ESR1 and ERBB2
gene expression as recently published (supplementary Table S1, available at
Annals of Oncology online) [13].
microarrays
Using MapQuant Path kits (Ipsogen), frozen tumor samples (10 × 20-μm-
thick sections) immersed in RNAlater® and a representative hematoxylin
and eosin (H&E) slide from eligible patients were sent from the three
participating centers to a centralized laboratory (DNAVision, Charleroi,
Belgium) at room temperature. RNA extraction was performed on samples
containing a minimum of 30% invasive tumor cells on the representative
H&E slide. Cellularity was centrally evaluated at the IJB and subsequently
at the Institut de Pathologie et de Génétique (Charleroi, Belgium).
Microarray analyses were performed using Affymetrix U133 Plus 2.0 arrays
at DNAVision. GG was computed using the Ipsogen MapQuant Dx
protocol (supplementary Table S2, available at Annals of Oncology online),
which deﬁnes tumors as low GG (GG1) or high GG (GG3), based on GG
values. To ensure robustness and accuracy of genomic grading as per
the MapQuant protocol, when the GG value of a sample could not be
ascribed with a probability ≥75% to either GG1 or GG3, it was deﬁned as
equivocal.
study end points
The grading classiﬁcation performance of GG was evaluated in the overall
population and in the subsets of classical and PILC. The associations
between GG, invasive disease-free survival (IDFS) and overall survival (OS)
were evaluated. IDFS was deﬁned as the interval between the date of breast
surgery and the date of any invasive breast recurrence (local, regional,
contralateral breast, distant) or death [14]. Patients still alive at the last
follow-up and with no evidence of any invasive breast disease were
censored. OS was deﬁned as time from breast surgery to death from any
cause, with patients still alive at the last follow-up being censored.
statistical analysis
GG and HG classiﬁcation were compared using cross-tabulation. IDFS and
OS were estimated by Kaplan–Meier curves. The median follow-up was
evaluated by the reverse Kaplan–Meier method.
The prognostic value of GG was evaluated by log-rank tests and
multivariate Cox regression analyses, both stratiﬁed by center. Cox models
included age (categories), pathologic tumor size (categories), number of
histologically involved nodes (categories), HG (1, 2 or 3), HER2 status
(negative or positive), ILC histotype (classical or PILC) and adjuvant
systemic chemotherapy. The signiﬁcance of individual variables in the Cox
model was evaluated using Wald statistics. The proportional hazards
assumptions were tested by including interactions with log(time) in the
models. There was no global signiﬁcant non-proportional hazards pattern.
The added value of GG both as a continuous variable and using the three
categories (GG1, equivocal and GG3) to classical clinicopathologic
variables was assessed by the likelihood ratio test (Δx2) in the Cox
regression models. The concordance-index (c-index) was computed to
evaluate the added discrimination of GG to the clinicopathologic variables
included in the Cox regression models.
Three different models were evaluated: (i) clinicopathologic variables
alone (tumor size, nodal status, HG, ILC histotype, adjuvant
chemotherapy); (ii) clinicopathologic variables plus continuous genomic
grade index (GGI); (iii) clinicopathologic variables plus categorical GG.
The larger the c-index, the better the predictability of a survival model: a
value of 0.5 refers to no predictive discrimination, and a value of 1
indicates perfect discrimination of patients with different outcomes [15].
Cubic splines with 3 degrees of freedom were ﬁtted to GGI in order to
visualize its continuous relationship with 5-year predicted IDFS.
results
study population
A total of 243 tumor samples were sent for analysis, of which
225 had sufﬁcient invasive tumor cells for the analysis. GG was
successfully obtained for 174 samples. After merging the
genomic and clinical datasets, eight patients were excluded as a
result of clinical characteristics (four with mixed tumor
histology, two with metastatic disease and two with non-breast
synchronous malignancies). The 166 assessable patients were
diagnosed between 1994 and 2005, with the exception of ﬁve
patients diagnosed between 2005 and 2008. The median
follow-up time among the 166 patients was 6.5 years (95% CI
5.7–9.3 years). The clinicopathologic characteristics of included
patients are shown in Table 1. A total of 94% (156) and 95%
(157) of patients were characterized as ER-positive by local
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assessment and ESR1 gene expression, respectively. The overall
discordance rate between genomic and IHC ER assessment was
only 4.8% (8 of the 166 tumors). In the overall population, 43
patients (26%) experienced an IDFS event, and 20 patients
(12%) an OS event. IDFS events according to nodal status were
distributed as follows: node-negative, 11 (13%); 1–3 positive
nodes, 12 (25%); and ≥4 positive nodes, 19 (63%). One IDFS
event occurred in a patient with unknown nodal status. In the
classical (n = 144) and PILC (n = 22) histotypes, 36 (25%) and
7 (32%) patients, respectively, experienced an IDFS event.
histologic and GG classiﬁcation
In this study, 33 (20%) patients were classiﬁed as HG1, 120
(73%) as HG2 and 12 (7%) as HG3, as detailed in Figure 1.
GG classiﬁed 106 (64%) tumors as GG1, 29 (17%) as GG3 and
31 (19%) as equivocal. Within the HG2 subgroup representing
73% of the cohort, GG reclassiﬁed 78% of the cases (n = 94)
into GG1 (81%) and GG3 (19%), respectively. The overall
concordance between HG1/HG3 and GG1/GG3 was 90%. In
the subset of PILC, 1 (5%), 15 (68%) and 6 (27%) were
classiﬁed as HG1, HG2 and HG3, respectively. GG reclassiﬁed
the subset of PILC into 6 GG1 (27%), 6 GG3 (27%) and 10
equivocal (46%). When treating GG as a continuous variable
(GGI), the median value was −0.70 (min–max −0.30 to 2.0;
interquartile range: −1.63 to 0.10).
survival analysis: GG versus HG
The Kaplan–Meier curves for IDFS and OS are illustrated in
Figure 2. GG was signiﬁcantly associated with IDFS [hazard
ratio (HR); HRGG3 vs GG1 = 3.3 (1.7–6.8), P = 0.001] when
compared with HG [HRHG3 vs HG1 = 2.5 (0.9–7.1), P = 0.09].
Five-year IDFS values were 4.0 years (95% CI 3.4–4.5) for GG3
tumors and 4.7 years (95% CI 4.6–4.9) for GG1 tumors.
Similarly, GG yielded a statistically signiﬁcant prognostic value
for OS [HRGG3 vs GG1 = 3.1 (1.0–9.3), P = 0.04], which was not
observed for HG [HRHG3 vs HG1 = 2.7 (0.5–13.5), P = 0.23].
Five-year OS values were 4.5 years (95% CI 4.2–4.9) for GG3
tumors and 4.9 years (95% CI 4.8–5.0) for GG1 tumors.
survival analysis: GG versus Ki67
Ki67 labeling index using the pre-deﬁned 14% cut-off point
was not signiﬁcant for IDFS [HRKi67High vs Ki67Low = 1.8
(0.9–3.4), P = 0.09], nor for OS [HRKi67High vs Ki67Low = 1.3
(0.5–3.3), P = 0.58], as shown in supplementary Figure S1,
available at Annals of Oncology online. Ki67 evaluated as a
continuous variable was not associated with either IDFS
(HR for a one-unit increase in Ki67 HR = 1.0, P = 0.11) or
OS (HR = 1.0, P = 0.81). In contrast, a one-unit increase
in continuous GGI values corresponded to a signiﬁcant
HR of 1.7 (1.2–2.3) (P = 0.001) for IDFS and 1.6 (1.1–2.6)
(P = 0.03) for OS.
prognostic models using clinicopathologic
and GG data
Multivariate Cox proportional hazard models were built
to interrogate whether GG adds prognostic value to
clinicopathologic variables. Tables 2 and 3 described the Cox
proportional hazard models for IDFS and OS before and after
the addition of GG.3
As expected, nodal status was a strong prognostic factor for
both IDFS [HR≥ 4 positive nodes versus node negative = 10.7
(4.1–28.1), P < 0.0001] and OS [HR≥ 4 positive nodes versus
Table 1. Summary of demographics and clinical characteristics of patients
in the study
Patients
Center 1 117 (71%)
Center 2 12 (7%)
Center 3 37 (22%)
Age at diagnosis
Median (min–max) 59 (35–89)
<50 years 30 (18%)
≥50 years 136 (82%)
Tumor size
Median (min–max) 2.7 (0.9–17)
≤2 cm 57 (34%)
>2 cm 109 (66%)
Nodal status
Negative 86 (52%)
1–3 positive 48 (29%)
≥4 positive 30 (18%)
NA 2 (1%)
ER/PR status
ER+/PR+ 109 (66%)
ER+/PR− 47 (28%)
ER−/PR− 6 (4%)
ER−/PR+ 4 (2%)
HER2 statusa
Negative 157 (95%)
Positive 9 (5%)
ILC histotype
Classic 144 (87%)
Pleomorphic 22 (13%)
Histologic grade
HG1 33 (20%)
HG2 120 (72%)
HG3 12 (7%)
Unknown 1 (1%)
Ki67
Median 10 (0–60)
<14% 76 (46%)
≥14% 56 (34%)
Unknown 34 (20%)
Adjuvant therapy
No 3 (2%)
HRT 152 (92%)
CT 97 (58%)
Unknown 1 (2%)
Genomic grade
GG1 106 (64%)
Equivocal 31 (19%)
GG3 29 (17%)
Adj, adjuvant; HRT, hormonotherapy; CT, chemotherapy; ILC, invasive
lobular carcinoma.
aHER2 assigned according to ERBB2 gene expression.
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node negative = 36.9 (6.5–210.3), P < 0.0001]. Tumor size was a
prognostic factor for IDFS [HR > 2 versus ≤2 cm = 3.6 (1.3–
10.4), P = 0.01], but not for OS [HR > 2 versus ≤2 cm = 1.4
(0.3–6.4), P = 0.68]. HG (comparisons of HG2 versus HG1 or
HG3 versus HG1) did not have prognostic value in the models
either before or after the addition of GGI. Adjuvant
chemotherapy was signiﬁcantly associated with better
prognosis in both models for IDFS [HR = 0.4 (0.2–0.9), P =
0.02] and OS [HR = 0.3 (0.1–0.9), P = 0.04]. The PILC
histotype compared with classical ILC histotype was not
signiﬁcantly associated with worse prognosis in both models
for IDFS [HR = 1.8 (0.7–4.5), P = 0.24] and OS [HR = 1.7
(0.3–8.4), P = 0.51]. HER2 status was not a prognostic factor
for both IDFS and OS. In the model for IDFS, GG added
prognostic value to clinicopathologic variables [HRGG3 vs GG1
= 5.6 (2.1–15.3), Wald P < 0.001; HRGG equiv vs GG1= 2.8
(1.2–6.8), Wald P = 0.02; Δx2 = 12.1, likelihood ratio P = 0.002].
A worse OS was observed when GG was added to the
evaluated clinicopathologic variables [HRGG3 vs GG1 = 7.2, 95%
CI (1.6 to 32.2), Wald P = 0.01; HRGG equiv vs GG1 = 3.4
(1.0–11.6), Wald P = 0.005; Δx2 = 12.1; likelihood ratio
P = 0.002]. The addition of GGI as a continuous variable to the
same clinicopathologic variables yielded a signiﬁcant HR for
IDFS [HRGG cont = 2.1 (1.4–3.2), Wald P < 0.0001; Δx
2 = 13.5,
likelihood ratio P < 0.0001] and for OS [HRGG cont = 2.2
(1.2–4.0), Wald P = 0.01; Δx2 = 6.4, likelihood ratio P = 0.01].
The c-index showed increased predictive accuracy when GGI
was added to clinicopathologic variables. The ﬁrst model
containing clinicopathologic variables yielded a c-index of 0.75
(95% CI 0.65–0.85), while the same model plus continuous or
categorical GGI yielded c-indices of 0.79 (95% CI 0.71–0.87)
and 0.81 (95% CI 0.75–0.88), respectively. The probability of a
patient remaining free of an IDFS event at 5 years as a function
of increasing GGI values is shown in Figure 3.
discussion
The presented results showed that GG added prognostic value
to classic clinicopathologic variables in patients with ILC.
Importantly, the lack of a subset of untreated patients with
endocrine and/or chemotherapy and the possible interactions
of adjuvant therapy on survival are limiting factors in the
evaluation of the prognostic value of GG on patient’s outcome.
Previous analyses of series of tumors have demonstrated a
signiﬁcant prognostic value for HG in ILC [16–18]. In the
largest series [18], HG was evaluated across 517 cases of ILC
and signiﬁcantly associated with patient outcome. However,
34% of the included cases had non-classical histotypes of ILC
(solid, alveolar, tubulobular and lobular mixed), which are
often characterized as having either higher mitotic count or
presence of tubule formation (the latter being absent in
classical ILC). When the tubule formation component of HG
was excluded from that analysis, there was no longer a
statistically signiﬁcant association between the remaining
components (nuclear pleomorphism plus mitotic count) and
prognosis.
Importantly, in a retrospective series including 931 ILC
cases, Iorﬁda et al. [19] showed worse patient outcomes for
non-classical ILC variants when compared with classical ILC
cases. In the present series, 87% and 13% of tumors were
classiﬁed as classical and PILC, respectively. In agreement with
previous results, a trend towards worse outcome was observed
among PILC patients.
Figure 1. Distribution of histologic grade and genomic grade according to invasive lobular carcinoma histotype. GG, genomic grade; HG, histologic grade;
ILC, invasive lobular carcinoma.
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Until now, classic ILC and PILC tumors were considered
to be low-to-intermediate-grade and high-grade tumors,
respectively. However, in the present series, 30% of classic ILC
tumors are characterized as GG3 or GG equivocal, and up to
30% of PILC are characterized as GG1. Moreover, we observed
5% (9) of HER2-positive cases in the present series including
seven classical ILC and 2 PILC.
In a previous restrospective analysis of 13 International
Breast Cancer Study Group (IBCSG) studies, 767 ILC patients
were identiﬁed and compared with 8607 IDC patients. The ILC
subgroup was enriched for older patients (>50 years) and had a
higher frequency of HG2 and ER-positive tumors than the IDC
subgroup. In addition, IDC patients had better OS within the
ﬁrst 10 years after diagnosis when compared with ILC, but the
opposite effect was observed with longer follow-up. Similar to
the IBCSG studies, our series is mostly represented by patients
older than 50, whose tumors largely classiﬁed as HG2 (72%)
and ER-positive (94%). In contrast to the IBCSG series, the
present study has a shorter median follow-up, and it is not
clear whether GG can identify patients with a higher chance to
experience a late OS event (>10 years).
Older age at diagnosis and high-ER-positivity rates have
been consistently reported across different ILC series and are
important factors commonly taken into consideration for
adjuvant treatment decision making [20]. However, ILC
tumors do not respond consistently well to chemotherapy [3],
compounding the uncertainties associated with making
appropriate treatment decisions for this group of patients.
In our series, the beneﬁt conferred by chemotherapy could be
linked to the considerable percentage of ILC tumors
Figure 2. Kaplan–Meier plots of invasive disease-free survival and overall survival by genomic grade (A) and histologic grade (B).
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Table 2. Multivariate Cox proportional hazard models of IDFS stratiﬁed
by center
HR 95% CI P-value
Model 1: without genomic grade
Age
<50 1
≥50 2.3 0.9–6.3 0.10
ILC histotype
Classic 1
Pleomorphic 2.1 0.8–5.3 0.12
Tumor size
<2 cm 1
≥2 cm 2.7 1.0–7.3 0.05
Nodal status
Negative 1
1–3 positive 2.0 0.8–4.9 0.12
≥4 positive 9.8 3.8–25.3 <0.0001
Histologic grade
1 1
2 0.6 0.3–1.3 0.18
3 0.9 0.3–3.1 0.92
HER2
Negative 1
Positive 2.7 1.0–7.6 0.06
Adjuvant chemotherapy
No 1
Yes 0.4 0.2–0.9 0.02
Model 2: with genomic grade
Age
<50 1
≥50 3.2 1.1–9.2 0.03
ILC histotype
Classic 1
Pleomorphic 1.8 0.7–4.5 0.24
Tumor size
<2 cm 1
≥2 cm 3.6 1.3–10.4 0.01
Nodal status
Negative 1
1–3 positive 1.9 0.8–4.8 0.15
≥4 positive 10.7 4.1–28.1 <0.0001
Histologic grade
1 1
2 0.4 0.2–0.9 0.03
3 0.4 0.1–1.4 0.13
HER2
Negative 1
Positive 1.1 0.3–3.5 0.91
Adjuvant chemotherapy
No 1
Yes 0.4 0.2–0.9 0.02
Genomic grade
1 1
Equivocal 2.8 1.2–6.8 0.02
3 5.6 2.1–15.3 <0.001
Δx2 = 12.1 0.002
CI, conﬁdence interval; HR, hazard ratio; ILC, invasive lobular carcinoma.
P-values correspond to Wald statistics unless speciﬁcally indicated; Δx2
P-value is based on the value of adding genomic grade to the model
containing all clinicopathologic variables.
Table 3. Multivariate Cox proportional hazard models of OS stratiﬁed by
center
HR 95% CI P-value
Model 1: without genomic grade
Age
<50 1
≥50 3.2 0.6–16.2 0.16
ILC histotype
Classic 1
Pleomorphic 2.3 0.5–11.5 0.30
Tumor size
<2 cm 1
≥2 cm 1.1 0.3–4.3 0.92
Nodal status
Negative 1
1–3 positive 2.7 0.5–14.3 0.23
≥4 positive 31.5 6.2–159.9 <0.0001
Histologic grade
1 1
2 0.6 0.2–2.4 0.49
3 0.8 0.1–5.6 0.85
HER2
Negative 1
Positive 0.3 0–2.8 0.30
Adjuvant chemotherapy
No 1
Yes 0.2 0.1–0.9 0.03
Model 2: with genomic grade
Age
<50 1
≥50 4.7 0.8–27.7 0.08
ILC histotype
Classic 1
Pleomorphic 1.7 0.3–8.4 0.51
Tumor size
<2 cm 1
≥2 cm 1.4 0.3–6.4 0.68
Nodal status
Negative 1
1–3 positive 2.6 0.5–14.1 0.27
≥4 positive 36.9 6.5–210.3 <0.0001
Histologic grade
1 1
2 0.4 0.1–1.6 0.21
3 0.3 0–2.2 0.23
HER2
Negative 1
Positive 0.1 0–1.5 0.10
Adjuvant chemotherapy
No 1
Yes 0.3 0.1–0.9 0.04
Genomic grade
1 1
Equivocal 3.4 1.0–11.6 0.005
3 7.2 1.6–32.2 0.01
Δx2 = 12.1 0.002
HR, hazard ratio.
P-values correspond to Wald statistics unless speciﬁcally indicated; Δx2
P-value is based on the value of adding genomic grade to the model
containing all clinicopathologic variables.
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characterized as GG equivocal and GG high, although the
retrospective nature of this study limits our ability to draw
deﬁnitive conclusions. In patients with IDC, the highly
proliferative ER-positive disease subset determined by GG or
other gene signatures represents the group most likely to
beneﬁt from adjuvant chemotherapy, while the low
proliferative ER-positive group is less likely to derive such
beneﬁt [12, 21–23].
In previous studies, GG has shown its ability to categorize
ER-positive IDC tumors into two subtypes with distinct
clinical outcomes [24]. In a retrospective analysis including 666
tumor samples, high GGI score was signiﬁcantly associated
with worse survival outcome in both treated and untreated
datasets [24]. A subsequent analysis of tumors from 229
patients treated with primary neoadjuvant chemotherapy
demonstrated a direct association between high GGI score and
better response to treatment [21].
Ki67 labeling index has also been used to stratify ER-positive
breast cancer into low and highly proliferative subtypes
[11, 12]. However, in our study, Ki67 evaluated either as a
continuous or as a dichotomous variable failed to predict
patient outcomes. Importantly, the lack of a centralized and
standardized Ki67 evaluation in the present study limits
deﬁnitive conclusions [25]. Moreover, the Ki67 cut point used
in the present analysis was deﬁned in a non-ILC breast cancer
population, making its applicability to ILC patients uncertain.
In summary, this study represents the ﬁrst attempt to
evaluate the prognostic value of GG in a population of ILC,
in particular with respect to HG. Similar to what we had
previously determined for IDC, tumor cell proliferation
evaluated through GG has important prognostic value for
patients with ILC, including those with node-positive disease,
adding prognostic information to classic clinicopathologic
variables. The present results have shed light on the prognosis
of ILC and may help guide the design of future clinical studies
enrolling patients diagnosed with ILC.
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The prognostic role of TGF-b signaling pathway in
breast cancer patients
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Background: The transforming growth factor-β (TGF-β) pathway has dual effects on tumor growth. Seemingly,
discordant results have been published on the relation between TGF-β signaling markers and prognosis in breast
cancer. Improved prognostic information for breast cancer patients might be obtained by assessing interactions among
TGF-β signaling biomarkers.
Patients and methods: The expression of nuclear Smad4, nuclear phosphorylated-Smad2 (p-Smad2), and the
membranous expression of TGF-β receptors I and II (TβRI and TβRII) was determined on a tissue microarray of 574
breast carcinomas. Tumors were stratiﬁed according to the Smad4 expression in combination with p-Smad2
expression or Smad4 in combination with the expression of both TGF-β receptors.
Results: Tumors with high expression of TβRII, TβRI and TβRII, and p-Smad2 (P = 0.018, 0.005, and 0.022,
respectively), and low expression of Smad4 (P = 0.005) had an unfavorable prognosis concerning progression-free
survival. Low Smad4 expression combined with high p-Smad2 expression or low expression of Smad4 combined with
high expression of both TGF-β receptors displayed an increased hazard ratio of 3.04 [95% conﬁdence interval (CI)
1.390–6.658] and 2.20 (95% CI 1.464–3.307), respectively, for disease relapse.
Conclusions: Combining TGF-β biomarkers provides prognostic information for patients with stage I–III breast cancer.
This can identify patients at increased risk for disease recurrence that might therefore be candidates for additional
treatment.
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